Researchers Find Evidence Confirming Economic Burden Caused by C. difficile Infections in IBD, Other Diseases

Researchers Find Evidence Confirming Economic Burden Caused by C. difficile Infections in IBD, Other Diseases
Recently, a group of interdisciplinary researchers from the University of Toronto (UT) released study findings from a systematic review of currently published research on inflammatory bowel disease and other diseases that showed the economic burden that is a consequence of the growing rate of Clostridium difficile (C. diff) infection seen throughout the healthcare systems in developed countries. The study, entitled, “The Economic Impact of Clostridium difficile Infection: A Systematic Review,” was published on-line in the April edition of the American Journal of Gastroenterology. C.diff is a spore-forming, bacterium that produces toxins that lead to a range of C. diff-associated disease (CDAD) states in humans such as mild diarrhea, colitis and possibly death. According to the CDC, antimicrobial use is the primary risk factor for development of CDAD for it disrupts normal bowel flora and promotes C. diff overgrowth. C. diff typically affects older or severely ill patients who are hospital inpatients or residents of long-term-care facilities. Recently, however, both the frequency and severity of health-care-associated CDAD has increased substantially. This increase has led to a significant increase in both fiscal and human resource utilization in healthcare. To understand the precise economic burden that is a consequence of this increase in resource utilizati
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *